Phase 3 program targeting a potential US$2.2B U.S. market opportunity505(b)(2) regulatory path leveraging prior human data to reduce risk, cost, and timeFDA-reviewed CMC package validated through prior ANDA approvalPatent coverage to 2036 for ketamine in Parkinson's and related motor disordersActive pharmaceutical partnering discussionsUpcoming catalysts (Q4 2025 - Q2 2026): FDA meeting, pivotal study readiness, pharma partnershipToronto, Ontario--(Newsfile Corp. - October 8, 2025) - PharmaTher Holdings Lt ...

TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to provide a corporate update following its recently announced sale of the Company’s Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP (the “Ketamine ANDA”). The transaction was a strategic sale of a single generic ketamine asset and th ...

Legal & Regulatory - "Ketamine Queen" 在 Matthew Perry 过量用药案中认罪 [1]

Legal & Crime - A woman known as the "Ketamine Queen" agrees to plead guilty for allegedly selling the fatal dose to actor Matthew Perry [1]

Legal & Crime - A woman known as the "Ketamine Queen" agrees to plead guilty for selling the fatal dose to actor Matthew Perry [1]

Core Insights - HOPE Therapeutics, Inc. has received final clearance from the Florida Agency for Health Care Administration to close the acquisition of Dura Medical LLC, which is a revenue-generating and EBITDA positive entity [1][8] - Dura Medical specializes in precision treatment for mental health and chronic pain, utilizing advanced interventional psychiatry procedures [2][8] - The acquisition is expected to enhance HOPE's revenue and EBITDA, contributing to its expansion in Florida and beyond [5][8] Company Overview - HOPE Therapeutics is a subsidiary of NRx Pharmaceuticals, focusing on building a network of interventional psychiatry clinics that provide treatments such as ketamine therapy and Transcranial Magnetic Stimulation (TMS) [9] - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal bipolar depression and PTSD [6] Dura Medical's Mission and Services - Dura Medical aims to reduce suicide rates in the community, with a goal to treat over 10,000 individuals by 2026 [4] - The clinic offers a comprehensive range of services, including Ketamine Infusion Therapy, TMS, and Spravato®, targeting conditions like depression, PTSD, and anxiety [2][3] Regulatory and Strategic Developments - The acquisition of Dura Medical is part of a broader strategy that includes previous acquisitions aimed at expanding coverage along the West Coast of Florida [8] - The intended closing of the acquisition is subject to standard closing conditions, indicating a structured approach to regulatory compliance [5][8]